Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126625001 | 12662500 | 1 | I | 20160728 | 20160817 | 20160817 | PER | US-ASTRAZENECA-2016SE82162 | ASTRAZENECA | 0.00 | F | Y | 0.00000 | 20160818 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126625001 | 12662500 | 1 | PS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | N | 20639 | TABLET | |||||||||
126625001 | 12662500 | 2 | SS | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 0 | 25 | MG | BID | ||||||||
126625001 | 12662500 | 3 | SS | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 0 | 50 | MG | TID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126625001 | 12662500 | 2 | Depression |
126625001 | 12662500 | 3 | Depression |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126625001 | 12662500 | Anxiety | |
126625001 | 12662500 | Decreased appetite | |
126625001 | 12662500 | Insomnia | |
126625001 | 12662500 | Tremor |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126625001 | 12662500 | 2 | 201606 | 0 |